Doug Carlson brings over 17 years of experience with a multi-disciplinary background in corporate finance, venture capital, M&A, business development and commercial operations with both large and emerging growth healthcare companies. Prior to joining Kyn Therapeutics, Doug spent the last six years with Collegium Pharmaceutical, Inc. (NASDAQ: COLL) and helped oversee the company’s development from a privately-held, clinical-development stage company to a publicly-traded commercial business. At Collegium, Doug led corporate development and strategy, commercial and business development initiatives, including all aspects of commercial operations.
Prior to Collegium, Doug was senior director, business development at BTG International (LSE: BTG), a global healthcare company focused on specialty pharmaceuticals and interventional medicine, where he was responsible for global specialty pharmaceutical M&A and licensing. Previously, Doug worked at Ovation Pharmaceuticals as senior director, corporate business development and strategy. He played a critical role in the sale of Ovation to H. Lundbeck in 2009, after which he was promoted to the head of U.S. corporate business development and strategy. Before joining the biopharma industry, Doug worked in the healthcare private equity group at Pequot Capital Management, and was also a member of the healthcare investment banking group at Cowen & Company. Doug received a Bachelor of Arts degree from Trinity College in Hartford, Connecticut.